Aktienanalyse wird geladen …
BSX · NYSE · Medical Devices · USA
44,70 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 20,07 Mrd. | 2,9 Mrd. | 1,94 $ | 1,49 Mrd. | 6,7 Mio · 0,4 % | 69 % | 14,4 % | 2,45 $ | 0,20 $ | — |
| 2024 | 16,75 Mrd. | 1,85 Mrd. | 1,25 $ | 1,49 Mrd. | 6 Mio · 0,4 % | 68,6 % | 11,1 % | 1,78 $ | 0,18 $ | — |
| 2023 | 14,24 Mrd. | 1,57 Mrd. | 1,07 $ | 1,46 Mrd. | 5,2 Mio · 0,4 % | 69,5 % | 11 % | 1,22 $ | 0,16 $ | — |
| 2022 | 12,68 Mrd. | 642 Mio. | 0,45 $ | 1,44 Mrd. | 4,9 Mio · 0,3 % | 68,8 % | 5,1 % | 0,65 $ | 0,15 $ | — |
| 2021 | 11,89 Mrd. | 985 Mio. | 0,69 $ | 1,43 Mrd. | 4,3 Mio · 0,3 % | 68,8 % | 8,3 % | 0,92 $ | 0,14 $ | — |
| 2020 | 9,91 Mrd. | -115 Mio. | -0,08 $ | 1,42 Mrd. | 3,8 Mio · 0,3 % | 65,1 % | -1,2 % | 0,80 $ | 0,12 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5,44 Mrd. | 907 Mio. | 0,61 $ | 1,47 Mrd. | 70,7 % | 16,7 % | 0,87 $ |
| Q1 2026 | 5,2 Mrd. | 1,34 Mrd. | 0,90 $ | 1,5 Mrd. | 69,5 % | 25,8 % | 0,11 $ |
| Q4 2025 | 5,29 Mrd. | 672 Mio. | 0,45 $ | 1,5 Mrd. | 69,6 % | 12,7 % | 0,68 $ |
| Q3 2025 | 5,07 Mrd. | 755 Mio. | 0,50 $ | 1,5 Mrd. | 69,9 % | 14,9 % | 0,78 $ |
| Q2 2025 | 5,06 Mrd. | 797 Mio. | 0,53 $ | 1,49 Mrd. | 67,7 % | 15,8 % | 0,76 $ |
| Q1 2025 | 4,66 Mrd. | 674 Mio. | 0,45 $ | 1,49 Mrd. | 68,8 % | 14,5 % | 0,24 $ |
| Q4 2024 | 4,56 Mrd. | 565 Mio. | 0,38 $ | — | 67,8 % | 12,4 % | 0,79 $ |
| Q3 2024 | 4,21 Mrd. | 469 Mio. | 0,32 $ | 1,49 Mrd. | 68,8 % | 11,1 % | 0,55 $ |
Wells Fargo Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Equalweight Rating
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know
Ammonix Launches a New AI Architecture for High-Stakes Specialist Agents That Outperform Frontier Models at a Lower Cost
Ammonix Launches a New AI Architecture for High-Stakes Specialist Agents That Outperform Frontier Models at a Lower Cost
Cordis wins FDA approval for sirolimus-eluting balloon
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology, and neuromodulation. Its MedSurg segment covers products for digestive health, urinary care, and pain management, while its Cardiovascular segment supports minimally invasive treatment options for heart and vascular conditions. Boston Scientific’s devices are designed to help healthcare professionals diagnose and treat patients through less invasive approaches across hospitals, clinics, and specialized medical centers. Headquartered in Marlborough, Massachusetts, Boston Scientific plays a significant role in the global health care equipment market through its broad mix of procedure-based products and physician-focused solutions.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest BSX und jede andere Aktie unbegrenzt.